President Donald Trump announced Wednesday that he intends to nominate Dr. Heidi Overton, a senior White House aide, to lead the Food and Drug Administration (FDA). Overton, currently the deputy director of the White House Domestic Policy Council, played a significant role in expediting an executive order aimed at accelerating research into psychedelic substances such as LSD and ibogaine.
This executive order directed the FDA to expedite its review process for drugs categorized as having "breakthrough therapy" status. The initiative reportedly gained traction after podcaster Joe Rogan brought attention to the potential benefits of psychedelics, particularly ibogaine's role in addressing opioid addiction, by contacting the President. Trump has referred to Overton as "Dr. Heidi" and a "rockstar" on his social media platform, Truth Social, praising her for her intelligence and commitment to his priorities of faster cures, innovation, and lower drug prices.
Overton, who holds a doctoral degree in clinical investigation from Johns Hopkins University, previously served as the chief policy officer at the conservative think tank America First Policy Institute. She has been a visible figure alongside Trump, participating in announcements for key administration projects, including drug pricing negotiations and a controversial order to separate the measles, mumps, and rubella (MMR) vaccine into individual components.
Health Secretary Robert F. Kennedy Jr. expressed support for Overton's nomination, citing her "exceptional judgment, professionalism, discipline and an unwavering commitment to the American people." However, the nomination faces scrutiny in the Senate. Louisiana Republican Sen. Bill Cassidy, chair of the Senate Health, Education, Labor, and Pensions Committee, acknowledged Overton's medical background but raised "strong concerns," citing her lack of managerial experience and her involvement in the vaccine order.
Washington Sen. Patty Murray voiced strong opposition, labeling Overton as a "far-right, anti-abortion extremist" who is unfit to lead the FDA. Overton's policy positions also include criticism of abortion pills, and she could potentially roll back regulations that increase their accessibility if confirmed.
Overton's confirmation requires approval from the narrowly Republican-controlled Senate. Her potential leadership at the FDA comes at a time of heightened public interest in psychedelic therapies and ongoing debates surrounding drug regulation and access.